Medical Condition News

RSS

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lennart Mucke, MD, Director of the Gladstone Institute of Neurological Disease (GIND), has been named a recipient of the American Academy of Neurology's prestigious Potamkin Prize.

19 Feb 2010

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows.

18 Feb 2010

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

One in eight women diagnosed with breast cancer is younger than 45 when diagnosed, yet their emotional and medical concerns are different than those of women over age 45, as is the impact of their diagnosis on family, friends, partners, colleagues and children.

18 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME).

18 Feb 2010

Charity Navigator bestows MMRF coveted 4-star rating for efforts in finding cure for multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) announced today that it has received a 4-star rating from Charity Navigator, America's largest independent evaluator of charitable donations, for demonstrating exceptional fiscal responsibility in its efforts to bring patients the next generation of treatments and find a cure for multiple myeloma. This is the seventh consecutive year the MMRF has been honored with this distinguished recognition.

18 Feb 2010

Long-term solution for U.S. medical isotope shortage needed

The medical community has taken additional steps to help alleviate ongoing challenges facing physicians and patients due to the worldwide isotope shortage. SNM cautions that while this is good news, a long-term solution for the U.S. is needed urgently.

18 Feb 2010

Revised and updated edition of Toole's Cerebrovascular Disorders textbook now available

Since it was published more than 40 years ago, Toole's Cerebrovascular Disorders has been a standard textbook for the prevention, diagnosis and treatment of strokes.

18 Feb 2010

Aprea's AML treatment receives EMEA recommendation for orphan drug status

The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.

18 Feb 2010

Single microRNA exhibits potential to forecast outcomes of MPM

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research.

18 Feb 2010

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.

18 Feb 2010

Easier walking for amputees: Artificial foot that recycles energy

An artificial foot that recycles energy otherwise wasted in between steps could make it easier for amputees to walk, its developers say.

18 Feb 2010

Pfizer Canada accepts entries for seventh round of competition for Pfizer CVRAP

Pfizer Canada is currently accepting entries for its seventh round of competition for the Pfizer Cardiovascular Research Awards program (CVRAP). The program, first launched in October 2005, was developed to fund and support independent cardiovascular research in Canada.

18 Feb 2010

AHA Scientific Statement: Only 33% of annual PCIs are performed in women

President Clinton’s stent surgery brought new focus to America’s number-one killer, but it did little to expose the bias that is often present when women seek treatment for a heart attack.

18 Feb 2010

Nanotechnology plays a key role in detection and treatment of cancer

A world-renowned medical researcher discusses the key role that nanotechnology has begun to play in the detection and treatment of cancer in an article that will appear in the March 2010 edition of Mechanical Engineering magazine.

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Medical Condition News

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lower dose of avosentan drug may provide more favorable results in diabetes patients

FDA approves Rituxan-FC combination therapy for CLL

Rituxan, intended for patients with CLL receives FDA approval

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Charity Navigator bestows MMRF coveted 4-star rating for efforts in finding cure for multiple myeloma

Long-term solution for U.S. medical isotope shortage needed

Revised and updated edition of Toole's Cerebrovascular Disorders textbook now available

Aprea's AML treatment receives EMEA recommendation for orphan drug status

Single microRNA exhibits potential to forecast outcomes of MPM

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Easier walking for amputees: Artificial foot that recycles energy

Pfizer Canada accepts entries for seventh round of competition for Pfizer CVRAP

AHA Scientific Statement: Only 33% of annual PCIs are performed in women

Nanotechnology plays a key role in detection and treatment of cancer

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News